September 4, 2014 | NeuroDerm, a clinical-stage pharmaceutical company developing drugs for neurodegenerative diseases, announced the success of a Phase IIa clinical trial of their drug for Parkinson’s disease. Patients with serious to severe Parkinson’s disease were given the company’s ND0612H drug formulation that is continuously delivered through a belt pump. This solution suits severe cases of Parkinson’s disease that would normally require surgical procedures, instead administering drugs through a belt. The study was supported by a grant from The Michael J. Fox Foundation for Parkinson’s Research, with the final results of the trial expected in the fourth quarter of 2014.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Clean Energy Firm Completes Solar Project In North, South Israel
October 15, 2024
Cannabis Therapy Firm: CBD Jab Reduces Pain In Arthritic Dogs
October 15, 2024
US Government Funding Development Of Israeli Ebola Treatment
October 14, 2024
Security Firm Wins Prison Service Contract For Electronic Monitoring
October 14, 2024
Facebook comments